Fig. 5
From: Knockdown of IGF2BP2 overcomes cisplatin-resistance in lung cancer through downregulating Spon2 gene
IGF2BP2 was apparently elevated in relapsed LC tissues. (A) RT-qPCR was performed to assess IGF2BP2 levels in adjacent normal tissues, tumor tissues and relapse/resistant tumor tissues (poor response to DDP therapy). (B) IF staining assay was used to determine IGF2BP2 and CD133 levels in adjacent normal tissues, tumor tissues and relapse/resistant tumor tissues (scale bar, 100 μm). **P < 0.01; ***P < 0.001